Wockhardt Limited — PPTs, 05-06-2025: Investor Presentation

1. Financial Highlights:

Wockhardt posted revenues of INR 3,033 Cr, up 5% YoY. EBITDA surged 67% to INR 418 Cr, lifting margins to 14% from 9%. Net debt decreased by INR 397 Cr to INR 64 Cr, with a net debt-to-equity ratio of 0.01, highlighting a solid balance sheet and improved financial health.

2. Strategic Initiatives & Growth Drivers:

Growth is fueled by novel antibiotics, diabetes biosimilars, and biotech segments. Key launches include ZAYNICH® targeting multi-drug resistant infections globally and MIQNAF®, a macrolide antibiotic launched in India with planned expansions. Diabetes biosimilars capacity is set to double in three years, focusing on human insulin and analogues to capture a US$3 billion market. Manufacturing restructuring and energy cost optimization are also underway.

3. Business Developments:

ZAYNICH® completed successful global Phase III trials with superior efficacy; NDA filed in India and pre-NDA submitted to the US FDA. MIQNAF® is approved and launched in India, with breakthrough status in Saudi Arabia. Insulin Aspart filings are in progress in India. The company raised INR 1,000 Cr through QIP to support growth initiatives.

4. Market Position & Competitive Advantage:

Wockhardt’s scale spans 12 manufacturing sites and two R&D centers. It leads in novel antibiotics with six QIDP programs accelerating approvals. Its integrated diabetes biosimilars model leverages R&D to commercialization, benefiting from market gaps due to competitor exits. ZAYNICH® targets a US$7 billion market in the US and Europe; MIQNAF® addresses the large Indian respiratory segment (~INR 10,800 Cr).

5. Investor Implications:

An expanding novel drug portfolio alongside robust financials signals positive growth potential. The ramp-up in biosimilars and operational efficiencies underpin medium- to long-term value creation. Monitoring clinical approval timelines and market adoption of new antibiotics is necessary as execution risks remain.